Ethanol-induced increase in the metabolic clearance of 1,1,1-trichloroethane in human volunteers

Toxicological Sciences

Volumn 92, Issue 1, 2006, Pages 61-70

  Johns, Douglas O ^a   Daniell, William E ^a   Shen, Danny D ^a   Kalman, David A ^a   Dills, Russell L ^a   Morgan, Michael S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

1,1,1 trichloroethane; Biotransformation; Enzyme induction; Ethanol; Methyl chloroform

Indexed keywords

1,1,1 TRICHLOROETHANE; ALCOHOL; ORGANIC SOLVENT; TRICHLOROACETIC ACID; TRICHLOROETHANOL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIOTRANSFORMATION; BLOOD ANALYSIS; BLOOD SAMPLING; CHEMICAL ANALYSIS; CONTROLLED STUDY; DETOXIFICATION; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER CLEARANCE; LIVER FUNCTION; LIVER METABOLISM; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; URINALYSIS; VOLUNTEER;

ADULT; ETHANOL; FEMALE; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; TRICHLOROETHANES;

EID: 33745594789     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj210     Document Type: Article

References (36)

1. American Conference of Governmental Industrial Hygienists (ACGIH) (2004). Threshold limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. American Conference of Governmental Industrial Hygienists, Cincinnati, OH.
2. Agarwal, D. P. (2001). Genetic polymorphisms of alcohol metabolizing enzymes. Pathol. Biol. 49, 703-709.
3. Ali, N., and Tardif, R. (1999). Toxicokinetic modeling of the combined exposure to toluene and n-hexane in rats and humans. J. Occup. Health 41, 95-103.
4. Andersen, M. E. (1982). Recent advances in methodology and concepts for characterizing inhalation pharmacokinetics parameters in animals and man. Drug Metab. Rev. 13, 799-826.
5. Agency for Toxic Substances and Disease Registry (ATSDR) (1995). Toxicological Profile for 1,1,1-Trichloroethane. Agency for Toxic Substances and Disease Registry, Atlanta, GA.
6. Brady, J. F., Ishizaki, H., Fukuto, J. M., Lin, M. C., Fadel, A., Gapac, J. M., and Yang, C. S. (1991). Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol. 4, 642-647.
7. den Elzen, M. G., Swart, R. J., and Rotmans, J. (1992). Strengthening the Montreal protocol: Does it cool down the greenhouse? Sci. Total Environ. 113, 229-250.
8. Ernstgard, L., Warholm, M., and Johanson, G. (2004). Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br. J. Clin. Pharmacol. 58, 190-200.
9. Guengerich, F. P., and Shimada, T. (1991). Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem. Res. Toxicol. 4, 391-407.
10. Guengerich, F. P., and Shimada, T. (1998). Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res. 400, 201-213.
11. Gurtner, H. D., Walser, P., and Fassler, B. (1975). Normal values for pulmonary hemodynamics at rest and during exercise in man. Prog. Respir. Res. 9, 295-315.
12. Hamelin, G., Charest-Tardif, G., Truchon, G., and Tardif, R. (2005). Physiologically based modeling of n-hexane kinetics in humans following inhalation exposure at rest and under physical exertion: Impact on free 2,5-hexanedione in urine and on n-hexane in alveolar air. J. Occup. Environ. Hyg. 2, 86-97.
13. Harford, T. C., Parker, D. A., Grant, B. F., and Dawson, D. A. (1992). Alcohol use and dependence among employed men and women in the United States in 1988. Alcohol Clin. Exp. Res. 16, 146-148.
14. Hjelm, E. W., Lof, A., Sato, A., Colmsjo, A., Lundmark, B.-O., and Norstrom, A. (1994). Dietary and ethanol induced alterations of the toxikokinetics of toluene in humans. Occup. Environ. Med. 51, 487-491.
15. Holford, N. H. G. (1987). Clinical pharmacokinetics of ethanol. Clin. Pharmacokinet. 13, 273-292.
16. Howard, L. A., Micu, A. M., Sellers, E. M., and Tyndale, R. F. (2001). Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J. Pharmacol. Exp. Ther. 299, 542-550.
17. Iba, M. M., Fung, J., and Gonzalez, F. J. (2000). Functional CYP2E1 is required for the substantial in vivo formation of 2,5-hexanedione from n-hexane in the mouse. Arch. Toxicol. 74, 582-586.
18. Johns, D. O., Dills, R. L., and Morgan, M. S. (2005). Evaluation of dynamic headspace with gas chromatography/mass spectrometry for the determination of 1,1,1-trichloroethane, trichloroethanol, and trichloroacetic acid in biological samples. J. Chromatogr. B 817, 255-261.
19. Jones, A. W. (1983). Determination of liquid/air partition coefficients for dilute solutions of ethanol in water, whole blood, and plasma. J. Anal. Toxicol. 7, 193-197.
20. Kim, R. B., and Wilkinson, G. R. (1996). Watercress inhibits human CYP2E1 activity in vivo as measured by chlorzoxazone 6-hydroxylation. Clin. Pharmacol. Ther. 59, 170.
21. Kall, M. A., Vang, D., and Clausen, J. (1996). Effects of dietary broccoli on human in vivo drug metabolizing enzymes: Evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 17, 793-799.
22. Klotz, U., and Ammon, E. (1998). Clinical and toxicological consequences of the inductive potential of ethanol. Eur. J. Clin. Pharmacol. 54, 7-12.
23. Loizou, G. D., and Cocker, J. (2001). The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: A phenotyping study using chlorzoxazone. Hum. Exp. Toxicol. 20, 321-327.
24. Loizou, G. D., Jones, K., Akrill, D., Dyne, D., and Cocker, J. (1999). Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. Toxicol. Sci. 48, 170-179.
25. McCarver, D. G., Byun, R., Hines, R. N., Hichme, M., Wegenek, W. (1998). A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol. 152, 276-281.
26. Morgan, M. S., Dills, R. L., and Kalman, D. A. (1993). Evaluation of stable isotope-labeled probes in the study of solvent pharmacokinetics in human subjects. Int. Arch. Occup. Environ. Health 65, S139-S142.
27. Nolan, R. J., Freshour, N. L., Rick, D. L., McCarty, L. P., and Saunders, J. H. (1984). Kinetics and metabolism of inhaled methyl chloroform (1,1,1-trichloroethane) in male volunteers. Fundam. Appl. Toxicol. 4, 654-662.
28. Oneta, C. M., Lieber, C. S., Li, J., Ruttimann, S., Schmid, B., Lattmann, J., Rosman, A. S., and Seitz, H. K. (2002). Dynamics of cytochrome P4502E1 activity in man: Induction by ethanol and disappearance during withdrawal phase. J. Hepatol. 36, 47-52.
29. Paustenbach, D. J., Clewell, H. J., Gargas, M. L., and Andersen, M. E. (1988). A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. Toxicol. Appl. Pharmacol. 96, 191-211.
30. Pierce, C. H., Dills, R. L., Silvey, G. W., and Kalman, D. A. (1996). Partition coefficients between human blood or adipose tissue and air for aromatic solvents. Scan. J. Work Environ. Health 22, 112-118.
31. Recknagel, R. O., Glende, E. A., Ugazio, G., Koch, R. R., and Srinivasan, S. (1974). New data in support of the lipoperoxidation theory for carbon tetrachloride liver injury. Isr. J. Med. Sci. 10, 301-311.
32. Reitz, R. H., McDougal, J. N., Himmelstein, M. W., Nolan, R. J., and Schumann, A. M. (1988). Physiologically based pharmacokinetic modeling with methyl chloroform: Implications for interspecies, high dose/low dose, and dose route extrapolations. Toxicol. Appl. Pharmacol. 95, 185-199.
33. Sato, A., Nakajima, T., and Koyama, Y. (1981). Dose-related effects of a single dose of ethanol on the metabolism in rat liver of some aromatic and chlorinated hydrocarbons. Toxicol. Appl. Pharmacol. 60, 8-15.
34. Tardif, R., Laparé, S., Krishnan, J., and Brodeur, J. (1993). A descriptive and mechanistic study of the interaction between toluene and xylene in humans. Int. Arch. Occup. Environ. Health 65, S135-S137.
35. Tardif, R., Sato, A., Laparé, S., and Brodeur, J. (1994). Ethanol induced modification of m-xylene toxicokinetics in humans. Occup. Environ. Med. 51, 187-191.
36. A/Q ratios: Partial pressure-solubility diagram. J. Appl. Physiol. 37, 533-540.